TICKERNERD
Menu
AEONAEONHealthcare · Biotechnology

AEON Stock Forecast: AEON Biopharma, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.19

The 3 Wall Street analysts covering AEON Biopharma, Inc. hold a median 12-month price target of $1.2 — +524.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$9.6M
Ticker Nerd rank
48 / 100
Median analyst target
$1.20
Analysts covering
3
Ticker Nerd rank

AEON stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AEON Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
98
Size
93
Revisions
63
Issuance
60
Volatility
48
Growth
39
Momentum
27
Value
15
Quality
12

Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AEON stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AEON, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $1.00Median $1.20High $2.10

The green dot is the last close — the median target sits +524.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026HC Wainwright & Co.MaintainsBuy—
8 Oct 2025Aegis CapitalReiteratesBuy—
1 Oct 2024HC Wainwright & Co.ReiteratesBuy—
14 Aug 2024HC Wainwright & Co.MaintainsBuy—
10 July 2024HC Wainwright & Co.ReiteratesBuy—
30 May 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024HC Wainwright & Co.MaintainsBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—
17 Apr 2024HC Wainwright & Co.ReiteratesBuy—
18 Aug 2023HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AEON appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AEON analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

AEON Biopharma, Inc. (AEON) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.3×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
−0.5×

Cheaper than 94% of US stocks

EV / EBITDA
−0.5×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
71.3%

Higher than 95% of US stocks

Return on assets
−141.5%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AEON vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AEONAEON Biopharma, Inc.$9.6M
48
FBLGFibroBiologics, Inc.$9.6M
47
MTVAMetaVia, Inc.$9.6M
17
OSRHOSR Health, Inc.$9.7M
24
LNAILunai Bioworks, Inc.$9.8M
31
SKYESkye Bioscience, Inc.$9.8M
34
IMNNImunon, Inc.$9.2M
22

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AEON Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AEON news & analysis

AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®

GlobeNewsWire · 19 Aug 2026positive

AEON Biopharma reported expanded structural data supporting the molecular similarity of its candidate ABP-450 to BOTOX. Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed.

Why it matters — AEON watchers would care because the expanded structural evidence strengthens the case for ABP-450's molecular similarity to BOTOX, a key factor in the product's development and regulatory positioning.

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 12 Aug 2026positive

AEON Biopharma, Inc. reported its second quarter 2026 financial results and provided a corporate update. The company executed a $15.3 million financing that included milestone warrants, providing the potential for an additional $34.0 million in gross proceeds to support the continued advancement of its ABP-450 development program.

Why it matters — The new financing and potential additional capital could help fund the ongoing clinical development of AEON's lead candidate ABP-450, which is central to the company's future progress.

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

GlobeNewsWire · 3 Aug 2026positive

AEON Biopharma announced it received written notice from NYSE American confirming that the company has regained compliance with the exchange's continued listing standards relating to stockholders' equity. The notice was issued on August 3, 2026.

Why it matters — Regaining compliance removes the risk of delisting from NYSE American, allowing AEON to maintain its listing as it continues advancing ABP-450.

Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards

GlobeNewsWire · 27 July 2026positive

Bitget announced the addition of AEON (AEON) to its Launchpool platform and spot market, with 1.1 million in token rewards and spot trading for the AEON/USDT pair opening July 27, 2026.

Why it matters — This listing on a major exchange increases AEON's liquidity and accessibility for traders and investors.

FAQ

Frequently asked questions about AEON stock

What is the AEON stock price forecast for 2026-2027?

The 3 Wall Street analysts covering AEON Biopharma, Inc. have a median 12-month price target of $1.2, with estimates ranging from $1 to $2.1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AEON stock a buy right now?

Of the 3 analysts covering AEON Biopharma, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AEON Biopharma, Inc. 48 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AEON?

As at 22 Aug 2026, AEON Biopharma, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).

Will AEON stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +524.7% from the last close, and Ticker Nerd's factor model ranks AEON Biopharma, Inc. 48 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AEON stock forecast for 2030?

No analyst covering AEON Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AEON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $2.1 over the next 12 months.

What does AEON Biopharma, Inc. do?

Aeon Biopharma Inc. is a biopharmaceutical company focusing on the development and commercialization of therapeutic treatments across a broad spectrum of medical conditions.

What is the latest news on AEON?

The most recent item we track (GlobeNewsWire, 19 Aug 2026): "AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®". AEON Biopharma reported expanded structural data supporting the molecular similarity of its candidate ABP-450 to BOTOX. Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed.

Company

About AEON Biopharma, Inc.

Aeon Biopharma Inc. is a biopharmaceutical company focusing on the development and commercialization of therapeutic treatments across a broad spectrum of medical conditions. Its primary mission is to leverage innovative biotechnological advancements to improve patient outcomes, particularly in the realm of neurology and other chronic and debilitating disorders. Aeon Biopharma places significant emphasis on research and development, seeking to introduce novel therapies that can transform standard care practices. Operating within the dynamic pharmaceutical sector, the company has an impact on healthcare providers, regulatory bodies, and patients by advancing medical solutions that could potentially alleviate conditions previously thought to be untreatable. As an integral part of the biotechnology industry, Aeon Biopharma Inc. contributes to the broader medical innovation landscape, aiming to meet the growing demands for effective medical interventions by employing cutting-edge research methodologies and strategic partnerships.

CEO Mr. Robert Bancroft · 8 employees · United States · https://www.aeonbiopharma.com